Lysophosphatidic acid receptor antagonist and preparation method therefor
Certain compounds are lysophosphatidic acid receptor antagonists have high LPAR1 antagonist activity and selectivity, low toxicity, good metabolic stability, promising pharmaceutical development prospects, and may be used for preventing or treating LPAR1-related diseases or illnesses. The IC50 values of some of the compounds may be as low as 300 nM or below, even 50 nM or below. In addition, CC50 value range of the compounds may be as high as 200 μM or above. Furthermore, the compounds have good metabolic stability in humans, mice and rats.
1. A compound, a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a polymorph, an ester, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:
2. A pharmaceutical composition comprising one, two or more selected from the compound, the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the polymorph, the ester, and the pharmaceutically acceptable salt according to claim 1 .
3. A method for treating LPAR1-mediated conditions or diseases, comprising administering a therapeutically effective amount of the compound according to claim 1 , the stereoisomer, the tautomer, the nitrogen oxide, the solvate, the polymorph, the ester, or the pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the conditions or diseases are selected from organ fibrotic diseases, respiratory diseases, renal diseases, hepatic diseases, inflammatory diseases, neurological diseases, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, pains, urinary system diseases, ophthalmic diseases, metabolic diseases, cancers, and rejection of transplanted organs.